NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $420,930 | -65.3% | 16,559 | -50.7% | 0.04% | -52.7% |
| Q1 2023 | $1,214,459 | +61.8% | 33,595 | +77.2% | 0.07% | +51.0% |
| Q4 2022 | $750,737 | +48.7% | 18,958 | +64.5% | 0.05% | +81.5% |
| Q2 2022 | $505,000 | -27.1% | 11,528 | +20.4% | 0.03% | -25.0% |
| Q1 2022 | $693,000 | +0.1% | 9,577 | +12.2% | 0.04% | -14.3% |
| Q4 2021 | $692,000 | +6.1% | 8,539 | +52.4% | 0.04% | +13.5% |
| Q3 2021 | $652,000 | -14.8% | 5,603 | +21.4% | 0.04% | -9.8% |
| Q2 2021 | $765,000 | +60.0% | 4,617 | +34.9% | 0.04% | +51.9% |
| Q1 2021 | $478,000 | -8.1% | 3,423 | +13.9% | 0.03% | -28.9% |
| Q4 2020 | $520,000 | -79.8% | 3,005 | -83.8% | 0.04% | -54.8% |
| Q3 2020 | $2,580,000 | +73.2% | 18,521 | +48.5% | 0.08% | +121.1% |
| Q2 2020 | $1,490,000 | +87.2% | 12,474 | +56.7% | 0.04% | +81.0% |
| Q1 2020 | $796,000 | -16.6% | 7,959 | -2.0% | 0.02% | +61.5% |
| Q4 2019 | $955,000 | +7.7% | 8,123 | -21.3% | 0.01% | +30.0% |
| Q3 2019 | $887,000 | – | 10,316 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |